KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Korsana Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$31.41−0.97 (-3.00%)
Close on Oct 19, 2026
- Market cap
- $133.52M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Korsana Biosciences's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tomas Kiselak | 9,106,420 | 19.99% | 13D (active) | Sep 8, 2026 |
| Peter M. Hecht | 910,240 | 19.40% | 13D (active) amendment | Jul 16, 2026 |
| Abigail P. Johnson | 649,547 | 15.00% | 13G (passive) | Apr 30, 2026 |
| Venrock Healthcare Capital Partners XP, L.P. | 4,552,277 | 9.90% | 13D (active) | Sep 8, 2026 |
| GAP Coinvestments PE Holdco, L.P. | 3,201,131 | 6.80% | 13G (passive) | Sep 8, 2026 |
| Bam Gp LLC | 317,511 | 7.33% | 13G (passive) | Jun 30, 2026 |
| FMR LLC | 3,144,797 | 6.90% | 13G (passive) amendment | Sep 30, 2026 |
| ADAR1 Capital Management, LLC | 298,757 | 7.00% | 13G (passive) | Jun 30, 2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 2,775,788 | 6.10% | 13G (passive) | Sep 9, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan Violin | See Remarks, Director | 207,400 | 4.43% | Sep 10, 2026 |
| Regina Margaret Graul | See Remarks, Director | 156,152 | 3.34% | Aug 18, 2026 |
| Matthew James Leoni | Chief Medical Officer | – | – | Sep 10, 2026 |
| Mark J. Vignola | Chief Financial Officer | – | – | Sep 10, 2026 |
| Rhonda M. Chicko | Chief Financial Officer | 25,018 | 0.53% | Aug 18, 2026 |
| Michelle Patricia Pernice | Director | – | – | Sep 10, 2026 |
| Nimish P. Shah | Director | 4,549,585 | 97.19% | Sep 10, 2026 |
| Andrew Gottesdiener | Director | – | – | Sep 10, 2026 |
| Healthcare Co-Invest VI L.P. Fairmount | Director, 10% owner | – | – | Sep 10, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 9,103,729 | 194.47% | Sep 10, 2026 |
| Tomas Kiselak | Director, 10% owner | – | – | Sep 10, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | – | – | Sep 10, 2026 |
| Peter Evan Harwin | Director, 10% owner | – | – | Sep 10, 2026 |
| Heidi Henson | Director | – | – | Sep 10, 2026 |
| Peter M. Hecht | Director, 10% owner | 910,312 | 19.45% | Jul 20, 2026 |
| Michael J. Higgins | Director | 30,740 | 0.66% | Mar 27, 2025 |
| Path Capital LP Slate | 10% owner | 6,196,063 | 132.36% | Nov 25, 2024 |
| David Gerald Greenspan | 10% owner | 0 | – | Nov 25, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rhonda M. Chicko Chief Financial Officer | Aug 14, 2026 | Option exercise | +25,000 | $2.36 | $59.00K | 25,018 |
| Regina Margaret Graul See Remarks, Director | Aug 14, 2026 | Option exercise | +55,849 | $3.30 | $184.30K | 156,152 |
| Regina Margaret Graul See Remarks, Director | Aug 14, 2026 | Tax withholding | −48,629 | $3.79 | $184.30K | 107,523 |
| Peter M. Hecht Director, 10% owner | Jul 16, 2026 | Conversion | +351,037 | – | – | 910,240 |
| Michael J. Higgins Director | Mar 25, 2025 | Award | +9,090 | $2.75 | $25.00K | 30,740 |
| Peter M. Hecht Director, 10% owner | Mar 25, 2025 | Award | +181,818 | $2.75 | $500.00K | 559,203 |
| David Gerald Greenspan 10% owner | Nov 21, 2024 | Sale | −357,880 | $1.55 | $554.71K | 0 |
| Regina Margaret Graul President | Jan 1, 2024 | Award | +50,000 | – | – | 100,303 |
| Peter M. Hecht Director, 10% owner | Jan 1, 2024 | Award | +15,000 | – | – | 377,385 |
| Peter M. Hecht Director, 10% owner | Dec 1, 2023 | Award | +15,000 | – | – | 362,385 |
| Terrance McGuire Director | Nov 30, 2023 | Award | +5,000 | – | – | 5,552 |
| Peter M. Hecht Director, 10% owner | Nov 30, 2023 | Award | +20,000 | – | – | 347,385 |
| Errol B. Desouza Director | Nov 30, 2023 | Award | +20,000 | – | – | 50,000 |
| Errol B. Desouza Director | Nov 30, 2023 | Award | +30,000 | – | – | 30,000 |
| Steven Hyman Director | Nov 30, 2023 | Award | +20,000 | – | – | 20,000 |
| Terrance McGuire Director | Aug 9, 2023 | Sale | −8 | $3.40 | $27 | 0 |
| Peter M. Hecht Chief Executive Officer, Director, 10% owner | May 19, 2023 | Award | +225,000 | $8.68 | $1.95M | 327,385 |
| Peter M. Hecht Chief Executive Officer, Director | Jun 3, 2021 | Buy | +823,170 | $3.28 | $2.70M | 2,047,698 |
| David Gerald Greenspan 10% owner | Jun 3, 2021 | Buy | +961,538 | $3.12 | $3.00M | 7,157,601 |
| Terrance McGuire Director | Jun 3, 2021 | Buy | +3,322 | $3.12 | $10.36K | 24,957 |
| Terrance McGuire Director | Jun 3, 2021 | Buy | +92,831 | $3.12 | $289.63K | 697,313 |
| Peter M. Hecht Chief Executive Officer, Director | May 6, 2021 | Buy | +302,000 | $2.43 | $733.86K | 1,224,528 |
| Peter M. Hecht Chief Executive Officer, Director | May 5, 2021 | Buy | +398,001 | $2.53 | $1.01M | 922,528 |
| Peter M. Hecht Chief Executive Officer, Director | May 4, 2021 | Buy | +300,000 | $2.29 | $687.00K | 524,527 |
| Christopher I. Wright Chief Medical Officer | Feb 25, 2021 | Sale(10b5-1 plan) | −2,637 | $3.99 | $10.52K | 42,728 |
| Anjeza Gjino Chief Financial Officer | Feb 25, 2021 | Sale(10b5-1 plan) | −1,824 | $4.00 | $7.30K | 31,599 |
| Mark G. Currie President and CSO | Dec 28, 2020 | Sale | −20,107 | $3.01 | $60.52K | 251,648 |
| Andreas Busch Chief Innovation Officer | Nov 9, 2020 | Buy | +125,000 | $2.53 | $316.25K | 254,704 |
| William Huyett Chief Financial Officer | Nov 6, 2020 | Sale(10b5-1 plan) | −3,827 | $2.52 | $9.64K | 67,590 |
| William Huyett Chief Financial Officer | Feb 21, 2020 | Sale(10b5-1 plan) | −3,559 | $5.12 | $18.22K | 71,417 |
| Mark G. Currie President | Dec 30, 2019 | Sale | −25,000 | $2.48 | $62.00K | 271,755 |
| Mark G. Currie President | Dec 27, 2019 | Sale | −25,000 | $2.55 | $63.75K | 296,755 |
| Andreas Busch Chief Innovation Officer | Nov 15, 2019 | Buy | +125,000 | $1.82 | $227.50K | 125,000 |
| William Huyett Chief Financial Officer | Nov 8, 2019 | Sale(10b5-1 plan) | −3,922 | $2.05 | $8.04K | 74,976 |
| Peter M. Hecht Chief Executive Officer, Director | Jul 10, 2019 | Option exercise | +2,000 | $6.04 | $12.08K | 225,192 |
| Amy W. Schulman Director | Apr 8, 2019 | Buy | +604,482 | $16.00 | $9.67M | 604,482 |
| Amy W. Schulman Director | Apr 8, 2019 | Buy | +21,635 | $16.00 | $346.16K | 21,635 |
| Terrance McGuire Director | Apr 8, 2019 | Buy | +21,635 | $16.00 | $346.16K | 21,635 |
| Terrance McGuire Director | Apr 8, 2019 | Buy | +604,482 | $16.00 | $9.67M | 604,482 |
| Mark G. Currie President | Apr 2, 2019 | Buy | +270,107 | $14.81 | $4.00M | 321,755 |
| Peter M. Hecht Chief Executive Officer, Director | Apr 1, 2019 | Award | +221,736 | – | – | 221,736 |
| William Huyett Chief Financial Officer | Apr 1, 2019 | Award | +38,320 | – | – | 38,320 |
| William Huyett Chief Financial Officer | Apr 1, 2019 | Award | +39,172 | – | – | 78,898 |
| George H. Conrades Director | Apr 1, 2019 | Award | +2,421 | – | – | 4,334 |
| Marsha Fanucci Director | Apr 1, 2019 | Award | +13,671 | – | – | 13,671 |
| Marsha Fanucci Director | Apr 1, 2019 | Award | +3,279 | – | – | 16,950 |
| Mark G. Currie President | Apr 1, 2019 | Award | +51,648 | – | – | 51,648 |
| William Huyett Chief Financial Officer | Apr 1, 2019 | Award | +39,179 | – | – | 78,912 |
| William Huyett Chief Financial Officer | Apr 1, 2019 | Award | +38,327 | – | – | 38,327 |
| Kevin Churchwell Director | Apr 1, 2019 | Award | +2,421 | – | – | 2,421 |
| Amy W. Schulman Director | Apr 1, 2019 | Award | +3,279 | – | – | 7,508 |
| Amy W. Schulman Director | Apr 1, 2019 | Award | +4,229 | – | – | 4,229 |
| Ole Isacson Director | Apr 1, 2019 | Award | +2,421 | – | – | 2,421 |
| George H. Conrades Director | Apr 1, 2019 | Award | +2,421 | – | – | 2,421 |
| Stephanie Lovell Director | Apr 1, 2019 | Award | +2,421 | – | – | 2,421 |
| Terrance McGuire Director | Apr 1, 2019 | Award | +7,768 | – | – | 7,768 |
| Terrance McGuire Director | Apr 1, 2019 | Award | +3,279 | – | – | 3,279 |
| Terrance McGuire Director | Apr 1, 2019 | Award | +162 | – | – | 162 |
| Terrance McGuire Director | Apr 1, 2019 | Award | +6,911 | – | – | 6,911 |
| Peter M. Hecht Chief Executive Officer, Director | Apr 1, 2019 | Award | +485 | – | – | 485 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| B. De Souza Errol Director | Sep 23, 2026 | 4,903 | $171.56K | Sep 23, 2026 | Restricted Stock |
| B. De Souza Errol Director | Sep 22, 2026 | 100 | $3.50K | Sep 22, 2026 | Restricted Stock |
| B. De Souza Errol Director | Sep 18, 2026 | 2,139 | $74.84K | Sep 18, 2026 | Restricted Stock |